Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1970 1
1971 1
1972 1
1973 2
1974 2
1975 1
1977 1
1978 2
1980 2
1986 2
1995 2
1996 1
1997 2
1998 1
1999 1
2001 1
2005 2
2006 3
2007 10
2008 7
2009 7
2010 6
2011 5
2012 7
2013 14
2014 13
2015 6
2016 9
2017 12
2018 11
2019 7
2020 7
2021 7
2022 16
2023 14
2024 10
2025 13
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Results by year

Filters applied: . Clear all
Page 1
Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies.
Weiss L, Zhang D, Kunz WG, Boeck S, Curigliano G, Subbiah V, Lordick F, Brummer T, Westphalen CB, Boscolo Bielo L. Weiss L, et al. Among authors: boeck s. ESMO Gastrointest Oncol. 2025 Jan 14;7:100129. doi: 10.1016/j.esmogo.2024.100129. eCollection 2025 Mar. ESMO Gastrointest Oncol. 2025. PMID: 41646490 Free PMC article. Review.
Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.
Fietkau R, Ghadimi M, Grützmann R, Wittel UA, Jacobasch L, Uhl W, Croner RS, Bechstein WO, Neumann UP, Waldschmidt D, Boeck S, Moosmann N, Reinacher-Schick AC, Golcher H, Adler W, Semrau S, Lubgan D, Kallies A, Hecht M, Tischoff I, Tannapfel A, Frey B, Oettle H; CONKO Study Group. Fietkau R, et al. Among authors: boeck s. J Clin Oncol. 2026 Feb 10;44(5):430. doi: 10.1200/JCO-25-03004. Epub 2026 Jan 8. J Clin Oncol. 2026. PMID: 41505667 No abstract available.
Real-world analysis of immune checkpoint inhibitor efficacy and response predictors in patients treated at the CCCMunichLMU outpatient clinic.
Dorman K, Breitenwieser K, Fischer L, Zhang D, Probst V, Weiss L, Heinrich K, Kunz WG, Holch JW, Gießen-Jung C, Haas M, Boeck S, von Bergwelt-Baildon M, Landfarth T, Hornung R, Casuscelli J, Berger-Thürmel K, Heinemann V, Westphalen CB, Reischer A. Dorman K, et al. Among authors: boeck s. Sci Rep. 2025 Dec 8;15(1):43269. doi: 10.1038/s41598-025-30220-0. Sci Rep. 2025. PMID: 41361351 Free PMC article.
Correction: Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.
Dorman K, Auernhammer CJ, Spitzweg C, Schmidmaier R, Nölting S, Kroiss M, Reincke M, Schulz C, Angele M, Werner J, Schmid-Tannwald C, Rauch J, Zacherl M, Knösel T, Kumbrink J, Jung A, Klauschen F, Tufman A, Zhang D, Weiss L, Boeck S, von Bergwelt-Baildon M, Heinemann V, Westphalen CB, Heinrich K. Dorman K, et al. Among authors: boeck s. Target Oncol. 2025 Sep;20(5):887. doi: 10.1007/s11523-025-01171-3. Target Oncol. 2025. PMID: 40864323 Free PMC article. No abstract available.
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.
Fietkau R, Ghadimi M, Grützmann R, Wittel UA, Jacobasch L, Uhl W, Croner RS, Bechstein WO, Neumann UP, Waldschmidt D, Boeck S, Moosmann N, Reinacher-Schick AC, Golcher H, Adler W, Semrau S, Lubgan D, Kallies A, Hecht M, Tischoff I, Tannapfel A, Frey B, Oettle H; CONKO Study Group. Fietkau R, et al. Among authors: boeck s. J Clin Oncol. 2025 Oct 20;43(30):3266-3278. doi: 10.1200/JCO-24-01502. Epub 2025 Aug 13. J Clin Oncol. 2025. PMID: 40802908 Clinical Trial.
Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.
Dorman K, Auernhammer CJ, Spitzweg C, Schmidmaier R, Nölting S, Kroiss M, Reincke M, Schulz C, Angele M, Werner J, Schmid-Tannwald C, Rauch J, Zacherl M, Knösel T, Kumbrink J, Jung A, Klauschen F, Tufman A, Zhang D, Weiss L, Boeck S, von Bergwelt-Baildon M, Heinemann V, Westphalen CB, Heinrich K. Dorman K, et al. Among authors: boeck s. Target Oncol. 2025 Jul;20(4):715-724. doi: 10.1007/s11523-025-01152-6. Epub 2025 Jun 30. Target Oncol. 2025. PMID: 40587033 Free PMC article.
[Correction: Version 3.1].
Seufferlein T, Mayerle J, Boeck S, Brunner T, Ettrich TJ, Grenacher L, Gress TM, Hackert T, Heinemann V, Kestler A, Sinn M, Tannapfel A, Wedding U, Uhl W. Seufferlein T, et al. Among authors: boeck s. Z Gastroenterol. 2025 Jul;63(7):783. doi: 10.1055/a-2618-6482. Epub 2025 May 27. Z Gastroenterol. 2025. PMID: 40425143 German. No abstract available.
[Correction: AWMF-Registernummer: 032-010OL - Leitlinie (Kurzversion)].
Seufferlein T, Mayerle J, Boeck S, Brunner T, Ettrich TJ, Grenacher L, Gress TM, Hackert T, Heinemann V, Kestler A, Sinn M, Tannapfel A, Uhl W, Wedding U. Seufferlein T, et al. Among authors: boeck s. Z Gastroenterol. 2025 Jul;63(7):783. doi: 10.1055/a-2618-6445. Epub 2025 May 27. Z Gastroenterol. 2025. PMID: 40425142 German. No abstract available.
PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer.
Rademaker G, Hernandez GA, Seo Y, Dahal S, Miller-Phillips L, Li AL, Peng XL, Luan C, Qiu L, Liegeois MA, Wang B, Wen KW, Kim GE, Collisson EA, Kruger SF, Boeck S, Ormanns S, Guenther M, Heinemann V, Haas M, Looney MR, Yeh JJ, Zoncu R, Perera RM. Rademaker G, et al. Among authors: boeck s. Nature. 2025 Jul;643(8074):1381-1390. doi: 10.1038/s41586-025-09017-8. Epub 2025 May 21. Nature. 2025. PMID: 40399683 Free article.
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study.
Mahajan UM, Oehrle B, Goni E, Strobel O, Kaiser J, Grützmann R, Werner J, Friess H, Gress TM, Seufferlein TW, Uhl W, Will U, Neoptolemos JP, Wittel UA, Vornhülz M, Sirtl S, Beyer G, Regel I, Boeck S, Heinemann V, Frost F, Steveling A, Völzke H, Petersmann A, Nauck M, Weber E, Kamlage B, Lerch MM, Mayerle J; METAPAC trial investigators. Mahajan UM, et al. Among authors: boeck s. Lancet Gastroenterol Hepatol. 2025 Jul;10(7):634-647. doi: 10.1016/S2468-1253(25)00056-1. Epub 2025 May 16. Lancet Gastroenterol Hepatol. 2025. PMID: 40388948 Free article. Clinical Trial.
188 results